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Detection	 of	 enzyme	 activity	 has	 gained	 popularity	 in	molecular	 imaging	 because	
increased	activity	of	enzymes	such	as	urokinase	plasminogen	activator	(uPA)	can	serve	as	
biomarkers	and	assist	 in	 cancer	diagnosis.	Chemical	 exchange	 saturation	 transfer	 (CEST)	
Magnetic	 Resonance	 Imaging	 (MRI)	 is	 a	 non-invasive	 technique	 that	 can	 be	 utilized	 to	
detect	 enzyme	 activity;	 however,	 CEST	 MRI	 is	 not	 the	 only	 technique	 that	 can	 assess	
enzyme	activity.	Chapter	1	provides	an	overview	of	various	 imaging	modalities	 that	have	
been	used	to	detect	enzyme	activity	in	vivo.	Advances	made	in	probe-design	are	discussed,	
in	 addition	 to	 advantages	 and	 disadvantages	 of	 each	 technique.	 Chapter	 2	 focuses	 on	
detection	 of	 uPA	 activity	 in	 a	 pancreatic	 cancer	 tumor	 model	 using	 a	 catalyCEST	 MRI	
contrast	agent.	Chapter	2	also	discusses	the	importance	of	uPA	in	tumor	biology,	addresses	
the	synthesis	of	the	contrast	agent,	and	evaluates	the	results	of	in	vivo	detection	and	ex	vivo	
validation	of	uPA	activity	 in	 response	 to	 therapy	of	pancreatic	 tumor	models	of	Capan-2.	
The	 in	vivo	 and	 ex	vivo	 results	 showed	 no	 significant	 difference	 in	 uPA	 activity	 between	
chemotherapy-treated	 and	 non-treated	 mice.	 Additionally,	 no	 significant	 difference	 was	
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processes.	 Abnormal	 enzyme	 activity	 can	 be	 a	 precursor	 for	 many	 human	 diseases.1	
Detecting	 enzyme	 activity	 in	 vivo	 can	 lead	 to	 faster	 and	 better	 diagnosis,	 and	 various	
imaging	 modalities	 can	 be	 used	 for	 this	 purpose.	 Each	 imaging	 technique	 has	 its	 own	
advantages	and	 limitations.	The	 techniques	 that	will	be	discussed	 in	 this	 chapter	 include	
the	 following:	 optical	 imaging,	 magnetic	 resonance	 imaging,	 radionuclide	 imaging,	 and	
photoacoustic	imaging.		
1.2 Optical	Imaging	
	 Optical	 imaging	 is	 a	 method	 in	 which	 photons	 being	 emitted	 by	 fluorescent	 or	
bioluminescent	probes	are	sensed	by	a	detector.	The	advantage	of	using	this	method	is	high	
sensitivity.2	The	limitation	of	this	imaging	modality	in	vivo	is	the	inability	of	light	to	travel	
from	 the	agent	 to	 the	detector	 through	deeper	 tissue.3	The	 signal	 from	 the	probe	 can	be	
scattered	and	absorbed	by	the	tissue.4	Also,	the	spatial	resolution	of	this	modality	is	low	(1-




	 Fluorescence	 imaging	 relies	 on	 the	 presence	 of	 fluorophore	 emitting	 light	 upon	
excitation.6	When	 the	 fluorophore	 is	 excited	 by	 the	 appropriate	wavelength	 of	 light,	 the	
emitted	 light	 of	 the	 shifted	 wavelength	 is	 detected	 by	 a	 charge-coupled	 device	 (CCD)	
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(Figure	 1.1).7	 Signal	 can	 be	 achieved	 with	 two	 types	 of	 probes	 when	 trying	 to	 detect	
enzyme	activity:	always-on	or	activatable.		
Always-on	and	Activatable	Probes	
	 Always-on	 and	 activatable	 probes	 produce	 florescence	 signal	 in	 different	 ways.	
Always-on	 probes	 are	 typically	 comprised	 of	 a	 fluorophore	 attached	 to	 an	 enzyme-
targeting	 ligand.	With	 a	 probe	 that	 is	 always	 fluorescent,	 signal	 at	 the	 site	 of	 the	 tumor	
depends	on	accumulation	of	enzyme-bound	fluorophores	and	the	excretion	of	non-bound	
fluorophores;	the	disappearance	of	non-bound	fluorophores	can	take	time	(Figure	1.2a).8	
Studies	 have	 shown	 that	 signal	 specific	 to	 the	 tumor	 site	 can	 be	 detected	 2-8	 h	 after	






activatable	 probes,	 fluorescence	 can	 initially	 be	 suppressed	 until	 the	 desired	 catalytic	
Figure	1.1.	Schematic	illustration	of	a	set	up	for	fluorescence	imaging.	
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reaction	 has	 occurred.	 Two	 fluorescence-suppressing	 mechanisms,	 which	 are	 enzyme	
specific,	will	be	discussed:	capped	and	pre-quenched	fluorophores.	
Capped	and	Pre-Quenched	Probes	





the	 fluorescence	 is	 recovered.	 The	 quenching	 of	 the	 fluorescence	 is	 caused	 by	 a	
phenomenon	 called	 Förster	 resonance	 energy	 transfer	 (FRET).3	 In	 FRET,	 the	 donor	
fluorophore	 is	 excited,	 but	 the	 energy	 is	 transferred	 to	 an	 acceptor,	 in	 this	 case,	 a	





the	 enzyme,	 and	 time	 is	 allowed	 to	 pass	 for	 the	 clearance	 of	 non-bound	 probe.	 (b)	 Once	 the	 activatable	 probe	 is	
added,	the	enzyme	activates	the	probe,	and	the	fluorescence	is	recovered	only	at	the	site	of	the	enzyme.	



















	 A	 variation	 of	 the	 fluorophore-quencher	 combination	 is	 fluorophore-fluorophore	
probe	with	a	 shifted	wavelength	 (Figure	1.3).	 In	 this	probe,	a	 fluorophore	 is	attached	 to	
another	 fluorophore	 by	 an	 enzyme-cleavable	 linker.	 Instead	 of	 the	 energy	 of	 the	 excited	
fluorophore	being	emitted	at	 the	wavelength	of	 the	donor	 for	detection,	 it	 is	relocated	to	
the	 acceptor	 fluorophore,	 and	 the	 emission	 occurs	 at	 the	 frequency	 of	 the	 acceptor	
fluorophore.	The	acceptor	fluorophore	has	an	absorption	spectrum	that	overlaps	with	the	
emission	 spectrum	of	 the	 donor	 fluorophore.	When	 the	 linker	 is	 cleaved,	 the	 absorption	
spectrum	of	the	acceptor	fluorophore	shifts,	allowing	the	emission	spectrum	of	the	donor	
fluorophore	to	be	detected.12	
	 Because	 of	 the	 shift	 in	 emission	 from	 fluorophore	 acceptor	 to	 fluorophore	 donor	
upon	 enzyme	 cleavage,	 FRET	 allows	 for	 ratiometric	 imaging	 to	 be	 used.	 Ratiometric	
imaging	 uses	 the	 ratio	 of	 two	 detected	 emission	 wavelengths	 to	 more	 quantitatively	
measure	 enzyme	 activity.13	 In	 the	 pre-quenched	 probe,	 the	 acceptor	 fluorophore	 has	 an	
emission	 at	 a	 certain	wavelength,	which	 is	 being	monitored	 by	 a	 detector.	 The	 emission	
wavelength	of	 the	donor	 is	also	monitored.	When	the	enzyme	cleaves	the	 linker	between	
the	 two	 fluorophores,	 the	 intensity	of	 the	donor	 fluorophore	 increases	as	 the	 intensity	of	
Figure	 1.3.	 Schematic	 illustration	 of	 enzymatic	 activation	 of	 fluorescent	 probes.	 Before	 the	 linker	 is	 cleaved,	


















	 While	 in	 vitro	 work	 can	 be	 done	 with	 a	 full	 color	 spectrum,	 in	 vivo	 imaging	 has	
issues	 with	 shorter	 wavelength	 light	 because	 of	 absorption	 by	 hemoglobin	 and	
autofluorescence	from	tissue.3	To	by-pass	this	issue,	near-infrared	(NIR)	probes	have	been	
developed	 and	 are	 being	 used.	 The	 NIR	 emission	 range	 is	 from	 700	 to	 900	 nm,6	 which	
allows	the	light	to	penetrate	several	centimeters.14	The	longer	wavelength	can	be	detected	
from	 deeper	 in	 the	 tissue	 than	 visible	 light	 and	 is	 the	 optimal	 range	 for	 a	 good	 balance	
between	deeper	tissue	penetration	and	low	autofluorescence.15	However,	 the	radiation	at	
this	 wavelength	 can	 cause	 tissue	 heating,	 so	 care	 must	 be	 taken	 to	 use	 an	 appropriate	
intensity	 and	 duration	 of	 NIR	 light.16	 There	 are	 three	major	 types	 of	 NIR	 probes:	 small	
molecules,	nanomaterials,	and	polymers.	
Small	Molecules	
	 Small	molecule	probes	 refer	 to	 lower	molecular	weight	organic	 compounds.	 Small	
molecules	make	desirable	probes	because	they	exhibit	fast	distribution	and	activation	(on	
the	order	of	30	minutes)	and	are	excreted	 in	a	 few	hours.3	This	 type	of	probe	allows	 for	




be	 capped	 and	 become	 fluorescent	 upon	 interacting	 with	 an	 enzyme.17	 This	 approach	
requires	a	change	in	the	electronic	properties	of	the	molecule	by	an	enzyme.3	Alternatively,	
small	molecule	 activity-based	 probes	 (ABP)	 can	 bind	 covalently	 to	 their	 enzyme	 targets,	
and	 the	bond	 is	usually	 irreversible.3	ABPs	 can	utilize	 either	 an	always-on	or	 activatable	
motif.	 For	 in	vivo	applications,	 it	 is	 more	 desirable	 for	 ABPs	 to	 have	 a	 quencher	 that	 is	
released	upon	binding	with	the	enzyme.3	Because	of	the	irreversible	binding,	the	ABPs	are	
not	excreted	from	the	organism	as	quickly	as	their	non-bound	counterparts.		
	 Lastly,	 small	 molecule	 probes	 can	 react	 with	 the	 enzymes	 of	 interest	 and	 self-
assemble	 into	 nanostructures.	 Typically,	 the	 probe	 will	 have	 a	 protecting	 group	 that	 is	
cleaved	 by	 the	 enzyme	 and	 allows	 for	 the	molecules	 to	 self-assemble.18	 The	 assembly	 of	
nanostructures	allows	for	the	fluorescence	to	be	much	brighter	against	the	noise,	making	
the	enzyme	activity	easier	to	detect.	Because	this	 is	a	newer	approach,	only	a	few	groups	
have	 demonstrated	 successful	 in	 vivo	 studies.19	 Even	 though	 self-assembly	 of	 small	
molecules	 into	 nanostructures	 is	 a	 relatively	 new	 field,	 there	 has	 been	 substantial	work	
done	with	nanomaterial	probes.	
Nanomaterials	
	 Due	 to	 the	 larger	 size,	 nanomaterial	 probes	 are	 able	 to	 produce	 much	 higher	
fluorescence;	 however,	 because	 of	 their	 size,	 these	 probes	 can	 take	 up	 to	 24	 hours	 to	
optimally	accumulate	at	their	target	site	and	can	take	days	to	be	excreted.3	Quantum	dots	
(QDs)	 are	 the	 most	 explored	 probes	 in	 the	 nanomaterial	 category	 for	 in	 vivo	 studies.	






high	quantum	yields,	and	high	resistance	 to	photobleaching.23	 In	addition	 to	having	 large	
excitation	and	narrow	emission	bands,	QDs	can	be	tuned	based	on	their	shape	and	size	to	
very	specific	wavelengths.22	Lastly,	QDs	have	a	relatively	long	fluorescence	lifetime.24	For	in	
vivo	 detection	 of	 enzyme	 activity,	 it	 has	 been	 shown	 that	 cleavable	 peptide	 chains	 with	
fluorescent	dyes	can	be	attached	to	QDs.	The	overlap	of	the	excitation	spectrum	of	the	dye	
and	 emission	 spectrum	of	 the	QD	 allows	 for	 FRET	 to	 emit	 the	QD	 signal	 until	 the	dye	 is	
released	from	the	QD	by	enzymatic	cleavage	of	the	peptide.25	Alternatively,	the	dye	on	the	
peptide	attached	to	the	QD	can	have	a	quencher	nearby,	and	once	the	dye	is	cleaved,	then	





































their	 small-molecule	 counterparts,	 which	 causes	 them	 to	 fluoresce	 much	 brighter.	
However,	 due	 to	 toxicity	 issues,	 QDs	must	 be	 coated	 before	 they	 can	 be	 injected	 in	vivo.	
Lastly,	 polymers	 allow	 for	 brighter	 fluorescence	 because	 of	 the	 number	 of	 dyes	 per	
molecule	is	much	larger	compared	to	small	molecule	probes.	However,	polymers	have	not	
been	 explored	 enough	 in	 vivo	 to	 make	 generalizations	 about	 the	 effectiveness	 and	
usefulness	 of	 these	 probes.	 Overall,	 fluorescence	 is	 a	 powerful	 and	 sensitive	 imaging	
modality	but	is	limited	to	superficial	locations	and	small	animal	work.	
1.2.2 Bioluminescent	Probes	
	 Bioluminescence	 is	 a	 type	 of	 chemiluminescence	 that	 occurs	 naturally	 though	 the	
enzymatic	 oxidation	 of	 luciferins	 by	 luciferase	 to	 form	 oxyluciferin	 and	 emit	 a	 photon.29	
Because	no	outside	 excitation	 is	needed	 (Figure	1.5),	 bioluminescence	 imaging	does	not	
suffer	 from	high	background	noise	due	to	autofluorescence	of	 the	tissues.3	There	are	two	












oxidize	 luciferin	 once	 the	 target	 enzyme	 has	 cleaved	 the	 linker,	 so	 bioluminescence	will	
only	 occur	 in	 the	 presence	 of	 the	 desired	 enzyme.	 However,	 because	 luciferase	 is	 not	
expressed	in	the	animals	that	are	being	 imaged,	 it	must	be	encoded	and	expressed	in	the	








linker	 (Figure	 1.6).3	 This	 type	 of	 imaging	 modality	 also	 requires	 the	 use	 of	 genetic	
modification,	 and	 several	 attempts	 have	 been	 successful	 in	 vivo.	 Luciferase	 has	 been	
modified	 to	 be	 connected	 between	 the	 N-terminus	 and	 the	 C-terminus	 by	 an	 enzyme-
specific	peptide	linker	(Figure	1.6a).33	Once	the	linker	was	cleaved,	luciferase	activity	was	
restored,	 and	 bioluminescence	 was	 observed	 at	 the	 site	 of	 the	 enzyme	 of	 interest.	 In	
another	 variation,	 luciferase	 was	 modified	 to	 have	 a	 bulky	 group	 attached	 at	 the	 N-
terminus	 and	 at	 the	 C-terminus	 by	 enzyme-specific	 cleavable	 peptide	 linkers	 (Figure	






	 Bioluminescence	 imaging	 allows	 for	 higher	 sensitivity	 than	 fluorescence	 imaging	
due	to	the	lack	of	background	noise.	However,	this	imaging	technique	is	highly	dependent	
of	the	ability	to	genetically	modify	tissues	in	order	to	express	luciferase.	Without	the	ability	
to	 inject	 luciferase	 reliably,	 bioluminescence	 imaging	 remains	 impractical	 for	 clinical	
studies.	
1.3 Magnetic	Resonance	Imaging	
Magnetic	 resonance	 imaging	 (MRI)	 is	 a	 technique	 that	 uses	 a	 radio	 frequency	 (RF)	
pulse	 to	 orient	 the	 spin	 state	 of	 the	 net	 protons	 away	 from	 the	magnetic	 field	 and	 then	
detects	 the	 time	 it	 takes	 for	 the	nuclei	 to	return	to	equilibrium.35	MRI	has	a	deep	 field	of	
view	and	high	spatial	resolution	but	suffers	from	relatively	poor	sensitivity.5	However,	the	
low	 sensitivity	 can	 be	 compensated	 for	 by	 the	 high	 turnover	 rate	 of	 an	 enzyme,	 which	
allows	 for	 activated	 contrast	 agent	 to	 reach	 a	detectable	 amount	with	 an	 “agent-limited”	
approach.36	 This	 approach	 incorporates	 an	 excess	 of	 contrast	 agent	 that	 is	 irreversibly	
changed	 by	 enzyme	 catalysis	 and	 therefore	 starts	 accumulating	 near	 the	 enzyme	 of	
Figure	 1.6.	 Activation	 of	 caged	 luciferase.	 (a)	 Luciferase	 can	 be	 caged	 by	 binding	 the	 N-terminus	 to	 the	 C-
terminus	with	a	 cleavable	 linker.	 Once	 the	 linker	 is	 cleaved,	 luciferase	 becomes	active	and	oxidizes	 luciferin	 to	
oxyluciferin	and	emits	a	photon.	(b)	Luciferase	can	also	be	caged	by	binding	bulky	groups	with	cleavable	linkers	

































from	its	equilibrium	state	 to	be	oriented	perpendicular	 to	 the	magnetic	 field.	The	excited	
net	 magnetic	 vector	 can	 relax	 back	 to	 equilibrium	 by	 two	 mechanisms.	 One	 of	 these	
mechanisms	 is	 longitudinal	 (T1)	 relaxation.	 The	T1	 relaxation	 time	of	water	 is	 shortened	







water	 accessibility.	 However,	 when	 the	 enzyme	 of	 interest	 removes	 the	 ligand,	 water	
accessibility	is	regained,	and	a	shorter	T1	time	is	observed.37	Another	approach	to	detecting	
enzyme	activity	is	to	have	an	enzyme	substrate	attached	to	the	chelate	that	upon	cleavage	








MR	 frequencies.36	 The	 relaxation	 time	 that	 is	 measured	 is	 T2*,	 which	 is	 the	 dephasing	
process	during	the	evolution	of	magnetism	of	water	molecules	at	different	frequencies	that	




iron	oxide	contrast	agent	 can	have	a	 solubilizing	 linker,	which	upon	cleavage	by	a	 target	
enzyme	 causes	 the	 nanoparticles	 to	 aggregate	 resulting	 in	 a	 decrease	 in	 T2*	 relaxation	





Chemical	 exchange	 saturation	 transfer	 (CEST)	 is	 an	 MRI	 contrast	 mechanism	 that	
reduces	 the	 signal	 of	 the	 bulk	 water	 after	 selective	 saturation	 at	 the	 frequency	 of	 an	
exchangeable	 proton	 on	 an	 MRI	 contrast	 agent.40	 Paramagnetic	 CEST	 (PARACEST)	 and	
diamagnetic	 CEST	 (DIACEST)	 agents	 can	 be	 used	 with	 this	 MRI	 mechanism.	 PARACEST	
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agents	are	metal	chelates	and	have	a	large	chemical	shift	from	the	water	peak	making	them	
easier	 to	detect.	 In	 comparison,	DIACEST	agents	 are	metal-free	organic	molecules,	which	
have	a	chemical	shift	within	10	ppm	of	the	water	peak.	Either	of	these	agents	can	be	used	to	
detect	enzyme	activity,	which	is	termed	“catalyCEST	MRI”.36	The	contrast	agent	can	have	an	
enzyme-cleavable	 ligand,	 and	when	 it	 is	 cleaved,	 the	 CEST	 effect	 appears	 or	 disappears.	
However,	 depending	 on	 a	 lack	 of	 signal	 before	 or	 after	 cleavage	 can	 be	 unreliable,	 and	
therefore,	 an	 internal	 CEST	 effect	 must	 be	 utilized	 as	 a	 control.36	 The	 internal	 control	
allows	for	a	ratiometric	comparison,	which	is	independent	of	the	concentration	of	contrast	
agent.44	PARACEST	and	DIACEST	agents	have	been	used	to	detect	enzyme	activity	by	 the	
use	 of	 cleavable	 substrates.45-46	 Overall,	 CEST	 MRI	 allows	 for	 the	 detection	 of	 enzyme	
activity	by	monitoring	 the	bulk	water	signal	and	seeing	a	change	 in	 the	CEST	effect	after	






relies	on	 the	 fast	 turnover	 rate	of	 the	enzyme.	With	 this	 approach,	 the	 sensitivity	 can	be	
improved	 by	 increasing	 the	 amount	 of	 contrast	 agent.	 T1	 contrast	 agents	 rely	 on	 a	 toxic	
metal	ion	but	provide	a	bright	contrast.	On	the	other	hand,	while	iron	oxide	nanoparticles	
are	 less	 dangerous,	 T2	 contrast	 agents	 show	 a	 dark	 contrast,	 which	 may	 be	 difficult	 to	





This	 type	 of	 imaging	 allows	 for	 high	 sensitivity	 (nM	 concentration)	 and	 high	 depth	 of	
penetration	 but	 low	 spatial	 resolution	 (1-2	 mm).5	 The	 field	 is	 split	 into	 two	 categories	
depending	 on	 which	 isotope	 is	 being	 detected:	 single	 photon	 emission	 computed	
tomography	(SPECT)	and	positron	emission	tomography	(PET).		
1.4.1 SPECT	and	PET	
SPECT	 often	 uses	 the	 following	 common	 isotopes:	 123I,	 99mTc,	 111In,	 and	 67Ga.	
Meanwhile,	PET	commonly	uses	18F,	11C,	13N,	15O,	64Cu,	76Br,	124I,	and	68Ga.3	The	radioactive	
isotopes	for	SPECT	have	a	longer	half-life	than	those	of	PET.	The	shorter	half-life	of	the	PET	
isotopes	 poses	 a	 problem	 in	 the	 timeliness	 of	 their	 synthesis	 and	 delivery.3	 Despite	 the	
short	half-life,	PET	is	a	major	imaging	modality	in	oncology	for	patients.48	In	PET,	decay	of	
radioactive	isotopes	emits	a	positron	that	travels	a	short	distance	before	it	annihilates	with	
an	 electron	 and	 releases	 two	 gamma	 rays	 in	 opposite	 directions,	 which	 are	 detected;	
meanwhile,	SPECT	detects	a	gamma	ray	that	is	emitted	from	the	radioactive	nucleus.47	The	
detection	of	 two	gamma	rays	per	radionuclide	 in	PET	allows	 for	better	spatial	 resolution	
relative	 to	 SPECT.47	 A	 widely	 used	 clinical	 probe	 for	 enzyme	 detection	 is	 18F-
fluorodeoxyglucose	(FDG),	which	is	detected	by	PET.49		
	 PET	and	SPECT	imaging	of	enzyme	activity	can	be	done	by	relying	on	the	principle	
that	 the	 enzyme-catalyzed	 product	 is	 trapped	 in	 cells.3	 This	 method	 works	 well	 for	
targeting	enzymes	like	kinases.	The	addition	of	a	charged,	bulky	group	to	the	probe	results	









isotopes.	 In	addition,	 the	 current	 strategies	 for	detecting	enzyme	activity	 can	only	detect	




	 Photoacoustic	 imaging	 is	 a	 relatively	 new	 technique.53	 In	 this	 technique,	 a	 short-
pulsed	laser	is	used	to	excite	the	molecule	of	interest.	The	excited	molecules	then	undergo	
thermo-elastic	 expansion,	which	 creates	 an	 acoustic	 signal	 that	 is	 detected	 by	 ultrasonic	
transducers	 surrounding	 the	 object.54	 The	 contrast	 of	 this	 technique	 comes	 with	 the	
sensitivity	of	optical	imaging	since	the	agent	is	excited	with	light,	but	the	spatial	resolution	
(~50	 µm)	 comes	 with	 ultrasonic	 detection.55	 However,	 despite	 the	 high	 sensitivity	 and	
resolution,	 little	work	has	been	done	with	photoacoustic	probes	 for	 enzyme	detection	 in	
vivo	 because	 of	 the	 lack	 of	 an	 efficient	 approach	 for	 probe	 design.6	 One	 way	 to	 utilize	
photoacoustic	 imaging	 for	 enzyme	 activity	 is	 to	 use	 optical	 probes.	 Once	 the	 activatable	





have	 an	 enzyme-cleavable	 linker.	When	 they	 are	 cleaved,	 the	molecules	 are	 able	 to	 self-




photoacoustic	 imaging	 a	 promising	 technique.	 However,	 more	 probes	must	 be	 designed	
and	tested	in	vivo	to	accelerate	this	field.	
1.6 Conclusion	
Detection	of	 enzyme	activity	 in	vivo	 has	gained	 significant	 interest	 in	 the	molecular	
imaging	 field.	 The	 imaging	modalities	 that	 have	 been	 explored	 for	 enzyme	detection	 are	
optical	 imaging	 including	 fluorescence	 and	 bioluminescence,	 MRI,	 radionuclide	 imaging	
including	SPECT	and	PET,	and	photoacoustic	imaging,	as	summarized	in	Table	1.1.	Optical	
imaging	 allows	 for	 high	 sensitivity	 but	 falls	 short	 with	 spatial	 resolution	 and	 depth	 of	
penetration.	MRI	allows	for	high	spatial	resolution	and	field	of	view	but	has	low	sensitivity.	
Radionuclide	 imaging	 has	 high	 sensitivity	 and	 field	 of	 view	 but	 has	 spatial	 resolution	
similar	 to	 optical	 imaging.	 Lastly,	 photoacoustic	 imaging	 has	 high	 sensitivity	 and	 spatial	
resolution	but	has	average	 field	of	view.	No	single	 imaging	modality	 is	 the	optimal	 fit	 for	
detecting	 enzyme	 activity;	 however,	 the	 innovative	 approaches	 to	 imaging	 probe	 design	
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Optical	Imaging MRI Radionuclide	Imaging PhotoacousticImaging
Sensitivity High Average High High
Spatial	Resolution Low High Low High
Depth of	Penetration/
Field	of	View Low High High Average
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DETECTION OF EARLY THERAPEUTIC 
RESPONSE BY MONITORING UROKINASE 
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targeted	 for	 ubiquitination	 and	 degraded.2	 Once	 NF-kB	 is	 activated,	 it	 can	 bind	 to	
designated	 sites	 on	 the	 chromatin	 to	 allow	 for	 the	 transcription	 of	 genes	 necessary	 for	
immune	and	inflammatory	response.		
In	 the	 mammalian	 immune	 and	 inflammatory	 regulation,	 NF-kB	 regulates	 the	
expression	of	a	wide	variety	of	genes.1	Pro-urokinase	plasminogen	activator	(uPA)	is	one	of	








proteasome	inhibitor,	which	 interferes	with	the	degradation	of	 IkB.	 If	 IkB	is	unable	to	be	
degraded,	then	NF-kB	remains	inactive,	and	pro-uPA	cannot	be	transcribed	and	translated.	
Because	the	precursor	is	no	longer	available,	the	amount	and	activity	of	uPA	is	decreased,	
and	 plasminogen	 is	 not	 converted	 plasmin,	 which	 slows	 invasion	 and	 metastasis.	
Therefore,	 we	 hypothesized	 that	 a	 decrease	 in	 uPA	 activity	 can	 be	 observed	 after	
administration	of	BTZ.	
2.1.2. CatalyCEST	MRI	to	Detect	uPA		
The	 ability	 to	 detect	 uPA	 in	vivo	 can	 potentially	 provide	 faster	 disease	 diagnosis,	
since	overexpression	of	uPA	is	considered	to	be	an	important	biomarker	in	breast,8	lung,9	
bladder,10	stomach,11	colorectum,12	cervix,13	ovary,14	kidney,15	and	brain	cancers.16		
CatalyCEST	MRI	 can	 be	 used	 to	 detect	 uPA	 activity	 in	vivo.	 In	 CEST	MRI,	 specific	
protons	on	the	contrast	agent	are	saturated	by	an	RF	pulse	(Figure	2.2a,b).	The	saturated	
proton	 can	 exchange	 with	 bulk	 water	 and	 decrease	 the	 water	 signal	 at	 that	 frequency	
Figure	 2.1.	 Diagram	 of	 the	 NF-kB	
pathway,	 highlighting	 the	 expression,	
activation,	 and	 function	 of	 uPA	 and	
inhibition	of	this	pathway	by	bortezomib.	
(1)	 NF-kB	 is	 signaled	 to	 bind	 IkB	 to	





uPAR.	 (6)	 uPA	 is	 activated.	 (7)	 uPA	
catalyzes	 plasminogen	 into	 plasmin.	 (8)	
































(Figure	 2.2c).	 In	 catalyCEST	 MRI,	 the	 CEST	 signal	 disappears	 after	 enzyme	 catalysis	
(Figure	2.2d).17	In this study, we proposed to use catalyCEST MRI to detect a therapeutic 





All	reactions	were	performed	under	an	inert	atmosphere	of	argon	equipped with a 
magnetic stirrer	 using	 dry	 solvents	 unless	 otherwise	 indicated.	 Flash	 column	
chromatography	was	performed	using	silica	gel	(particle	size	0.04-0.06	mm	and	230-400	Å	
mesh	 size).	 An	 analytical	 HPLC	 system	 (Agilent	 Technologies,	 1200	 series)	 and	 a	
preparative	HPLC	system	(Agilent	Technologies,	1260	series)	were	used	 for	analysis	and	
purification.	Reactions	were	monitored	using	thin	layer	chromatography	(TLC)	on	silica	gel	













Figure	 2.2.	Diagram	of	catalyCEST	MRI.	 (a)	The	representative	 initial	signals	of	 the	amide	and	water	protons.	 (b)	
The	 amide	 proton	 is	 selectively	 saturated	 (shown	 in	 red),	 and	 the	 signal	 of	 the	 proton	 is	 diminished.	 (c)	 Once	
chemical	exchange	occurs	between	the	amide	group	and	 the	water	molecule,	 the	amide	signal	 is	regained,	 but	the	




	 H" 	and	 C"$ 	NMR	spectra	were	 recorded	with	Bruker	AVIII	400	MHz	and	DRX	500	
and	600	MHz	NMR	instruments	(Bruker	Biospin,	Inc.,	Billerica,	MA).	Low	resolution	mass	
spectra	were	collected	with	an	Amazon	Ion	Trap	instrument	(Bruker	Biospin,	Inc.,	Billerica,	
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dry	 dimethyl	 formamide	 in	 a	 500	 mL	 round	 bottom	 flask,	 KOtBu	 (21.5	
mmol,	1.1	equiv,	2.4	g)	was	added	all	 at	once.	After	 the	 reaction	mixture	
was	cooled	to	0	°C,	benzyl	bromide	(21.6	mmol,	1.1	equiv,	2.6	mL)	was	added	drop-wise.	
The	reaction	mixture	was	allowed	to	warm	to	room	temperature	and	stir	for	5	h.	Then,	a	
second	 portion	 of	 KOtBu	 (21.5	 mmol,	 1.1	 equiv,	 2.4	 g)	 was	 added.	 After	 the	 reaction	
mixture	 was	 cooled	 to	 0	 °C,	 benzyl	 bromide	 (21.6	mmol,	 1.1	 equiv,	 2.6	mL)	 was	 added	
drop-wise.	The	reaction	mixture	was	allowed	to	warm	to	room	temperature	and	stir	for	16	
h	before	quenching	with	H%O.	The	solution	was	extracted	with	ethyl	acetate.	The	organic	
layer	 was	 washed	 with	 brine	 then	 concentrated,	 dried	 over	Na%SO*,	 filtered,	 and	 the	
solvent	 was	 removed	 by	 rotary	 evaporation.	 The	 crude	 mixture	 was	 purified	 by	 flash	





	Compound	 2	 was	 synthesized	 from	 a	 reported	 procedure	 with	
slight	 modifications	 (Scheme	 2.1).19	 Boc-Arg(Z)%-OH	 (7.8	 mmol,	 1.1	
equiv,	 4.2	 g)	 was	 dissolved	 in	 70	 mL	 tetrahydrofuran	 and	 treated	
dropwise	with	 anhydrous	pyridine	 (7.8	mmol,	 1.1	 equiv,	 0.63	mL)	 in	 a	













mmol,	 1.1	 equiv,	 3.9	 mL)	 was	 added,	 and	 the	 mixture	 was	 allowed	 to	 stir	 at	 room	
temperature	 for	 1	 h.	 Then,	 a	 solution	 of	 compound	 1	 (7.1	 mmol,	 2.4	 g)	 in	 15	 mL	
tetrahydrofuran	was	 added	 to	 the	 flask	 and	 the	 reaction	mixture	was	 allowed	 to	 stir	 at	
room	 temperature	 for	 30	 h.	 On	 completion,	 the	 reaction	mixture	was	 diluted	with	 ethyl	
acetate	and	washed	with	saturated	NaHCO$,	 followed	by	1	M	HCl,	and	water.	The	organic	
layer	 was	 washed	 with	 brine	 then	 concentrated,	 dried	 over	Na%SO*,	 filtered,	 and	 the	
solvent	 was	 removed	 by	 rotary	 evaporation.	 The	 crude	 mixture	 was	 purified	 by	 flash	







Compound	 3	 was	 synthesized	 from	 a	 reported	 procedure	 with	
slight	 modifications	 (Scheme	 2.1).20	 To	 a	 100	 mL	 round-bottom	 flask	
with	 compound	2	 (4.2	mmol,	 3.6	 g),	 4	M	HCl	 in	 dioxane	 (44	mL)	was	
added	cold	and	stirred	for	4	h	until	TLC	showed	that	no	starting	material	
remained	 (1:1	 ethyl	 acetate:hexanes).	 After	 the	 solvent	 was	 removed	 by	 rotary	
evaporation,	 the	 product	 was	 purified	 by	 preparative	 HPLC	 (RP	 C-18,	 10-90	 0.1%	
TFA:acetonitrile	in	45	min,	R7	=	29.39	min)	and	lyophilized	to	yield	compound	3	as	a	white	















OH	 (1.9	 mmol,	 1.1	 equiv,	 0.41	 g),	 2-(7-Aza-1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium	 hexafluoro-phosphate,	 (HATU,	 2.1	 mmol,	





bath	 was	 removed,	 and	 the	 reaction	 mixture	 was	 allowed	 to	 stir	 at	 room	 temperature	
overnight.	 The	 reaction	 mixture	 was	 diluted	 with	 ethyl	 acetate	 and	 washed	 with	 5%	
NaHCO$,	 5%	 citric	 acid,	 and	 water.	 The	 organic	 layer	 was	 washed	 with	 brine	 then	
concentrated,	 dried	 over	Na%SO* ,	 filtered,	 and	 the	 solvent	 was	 removed	 by	 rotary	
evaporation.	 The	 product	 was	 purified	 by	 preparative	 HPLC	 (RP	 C-18,	 10-90	 0.1%	






















in	 a	 250	mL	 round-bottom	 flask.	 To	 this	 solution,	 2M	 Boc-anhydride	 in	 tetrahydrofuran	
(4.2	mmol,	2.1	mL)	was	added,	and	the	mixture	was	allowed	to	stir	at	room	temperature	
for	 1	 h.	 Then,	 a	 solution	 of	 compound	 1	 (4.6	 mmol,	 1.1	 equiv,	 1.5	 g)	 in	 8	 mL	
tetrahydrofuran	was	 added	 to	 the	 flask	 and	 the	 reaction	mixture	was	 allowed	 to	 stir	 at	
room	 temperature	 for	 16	 h.	 On	 completion,	 the	 reaction	mixture	was	 diluted	with	 ethyl	
acetate	and	washed	with	saturated	NaHCO$,	 followed	by	1	M	HCl,	and	water.	The	organic	
layer	was	washed	with	brine	 then	 concentrated,	 dried	over	Na%SO*,	 and	 the	 solvent	was	
removed	 by	 rotary	 evaporation.	 The	 crude	 mixture	 was	 purified	 by	 flash	 column	
chromatography	over	SiO%	(3:7	 ethyl	 acetate:hexanes).	Multiple	 spots	were	 collected,	 but	
none	of	the	spots	were	identified	as	compound	4.	
Synthesis	of	Compound	5	
To	 synthesize	 compound	 5	 (Scheme	 2.1),	 compound	 4	 (0.56	
mmol,	 0.54	 g)	 was	 dissolved	 in	 48	 mL	 methanol	 in	 a	 250	 mL	 round-
bottom	flask,	and	0.4	mL	of	1	M	HCl	in	16	mL	ethyl	acetate	was	added	to	
the	 solution	 for	 solubility.	 A	 catalytic	 amount	 of	 Pd/C	 (15%	w/w)	 and	
Pd(OH)%	(15%	w/w)	were	added	to	the	reaction	mixture.	The	round-bottom	flask	was	then	
equipped	with	 a	H%	balloon	 and	 stirred	 for	 6	 h.	 The	 reaction	mixture	was	 passed	 over	 a	
medium	frit	filter	with	celite,	and	then,	the	solvent	was	removed	by	rotary	evaporation.	The	












acid:acetonitrile).	 The	 final	 compound	was	 purified	 by	 preparative	HPLC	 (RP	 C-18,	 0-30	
0.1%TFA:acetonitrile	in	45	min,	R7	=	13.06	min)	and	lyophilized	to	yield	compound	5	as	a	
white	solid	 (0.53	mmol,	0.20	g,	96%).	 H" 	NMR	(499	MHz,	D%O)	𝛿	7.83	 (d,	 J	=	8.7	Hz,	1H),	
7.18	(d,	J	=	2.0	Hz),	7.00	(dd,	J	=	8.7,	2.1	Hz,	1H),	4.48	(dd,	J	=	7.8,	6.1	Hz,	1H),	3.90	(s,	2H),	








material	 remained	 (1:1	 ethyl	 acetate:hexanes).	 After	 the	 solvent	was	 removed	 by	 rotary	
evaporation,	 the	 product	 was	 purified	 by	 preparative	 HPLC	 (RP	 C-18,	 10-90	 0.1%	
TFA:acetonitrile	in	45	min,	R7	=	16.12	min)	and	lyophilized	to	yield	compound	6	as	a	white	















diluted	 with	 ethyl	 acetate	 and	 washed	 with	 aqueous	 NaHCO$.	 The	 organic	 layer	 was	
washed	 with	 brine	 then	 concentrated,	 dried	 over	Na%SO*,	 filtered,	 and	 the	 solvent	 was	
removed	by	rotary	evaporation	to	yield	starting	material. 
Synthesis	of	Compound	7	
Compound	 7	 was	 synthesized	 (Scheme	 2.2)	 by	 dissolving	 Z-
Gly-OH	 (0.51	mmol,	 1.1	 equiv,	 0.11	 g),	 2-(7-Aza-1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium	 hexafluoro-phosphate,	 (HATU,	 0.55	





flask.	 The	 ice	 bath	 was	 removed,	 and	 the	 reaction	mixture	 was	 allowed	 to	 stir	 at	 room	
temperature	 overnight.	 The	 reaction	mixture	was	diluted	with	 ethyl	 acetate	 and	washed	
with	5%	NaHCO$,	5%	citric	acid,	and	water.	The	organic	layer	was	washed	with	brine	then	
concentrated,	 dried	 over	Na%SO* ,	 filtered,	 and	 the	 solvent	 was	 removed	 by	 rotary	
evaporation.	 The	 product	 was	 purified	 by	 preparative	 HPLC	 (RP	 C-18,	 10-90	 0.1%	














All	 in	 vivo	 studies	 were	 approved	 by	 the	 Institutional	 Animal	 Care	 and	 Use	
Committee	of	the	University	of	Arizona.	To	prepare	the	mouse	models	of	pancreatic	cancer,	
SCID	female	mice	that	were	6	weeks	old	were	injected	subcutaneously	with	1	×	106	Capan-




Inc.,	 Billerica,	MA)	operating	 at	 7.05	T	 (300	MHz)	magnetic	 field	 strength	with	 a	 72	mm	
quadrature	transceiver	coil.	To	detect	in	vivo	uPA	enzyme	activity,	catalyCEST	MRI	studies	
were	performed	with	10	mice	bearing	Capan-2	tumors.	Each	mouse	was	anesthetized	with	










min	 to	 incubate	 to	 allow	 for	 enzyme	 cleavage,	 the	 in	 vivo	 CEST-FISP	 MRI	 studies	 were	
carried	 out	 with	 the	 following	 parameters,	 TR:	 4.390	 ms;	 TE:	 1.995	 ms;	 excitation	 flip	
	 52	
angle:	 15°;	 with	 radiofrequency	 spoiling;	 centric	 encoding	 during	 acquisition;	 matrix:	
96×96;	field	of	view:	4.8x4.8	cm;	in-plane	spatial	resolution:	500x500	µm;	slice	thickness:	2	
mm;	number	of	slices:	1;	number	of	averages:	1;	total	scan	time:	5:34	min.	A	continuous	5	s	
wave	 pulse	 at	 a	 saturation	 power	 of	 4	 µT	was	 used	 at	 each	 saturation	 frequency.	 Each	
catalyCEST	MRI	scan	was	acquired	with	a	series	of	46	saturation	frequencies	at	ppm	values	
of	 +16,	 +15,	 +14,	 +13.8	 to	 3.0	 (with	 0.4	 ppm	 increments),	 +2.5	 to	 -2.0	 (with	 0.5	 ppm	
increments),	 and	 -3	 to	 -12	 (with	 2	 ppm	 increments).	 Twelve	 consecutive	 CEST	 spectra	








and	possible	heating	of	 the	static	shim	coils	or	sample.	A	 function	of	 four	Lorentzian	 line	
shapes	was	fit	to	each	CEST	spectrum	to	measure	the	signal	amplitudes	of	the	CEST	effects	
at	 5.0	 and	 9.5	 ppm,	 and	 also	 account	 for	 direct	 saturation	 of	water	 and	 the	 endogenous	
effect	 of	 amide	 proton	 transfer.23	 The	 saturation	 frequency,	width,	 and	 amplitude	 of	 the	
Lorentzian	line	shape	that	fit	the	direct	saturation	of	water	was	allowed	to	change	during	
the	 fitting	procedure.	The	width	and	amplitude	of	 the	 two	Lorentzian	 line	shapes	 that	 fit	
the	CEST	effects	of	the	agent	were	also	allowed	to	change,	but	the	saturation	frequencies	of	
these	 Lorentzian	 line	 shapes	 were	 fixed	 at	 9.5	 and	 5.0	 ppm	 relative	 to	 the	 saturation	
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frequency	of	the	direct	saturation	of	water.	The	parametric	maps	of	the	reaction	coordinate	





sterile	 saline.	CatalyCEST	MRI	studies	were	performed	3	h	after	 injection	using	 the	same	
CEST–FISP	 MRI	 protocol	 as	 used	 for	 the	 in	 vivo	 detection	 of	 enzyme	 activity.	 Control	
studies	were	also	performed	with	a	set	of	3	mice.	Sterile	 saline	 (150	µL)	was	 injected	 IV	
into	the	mouse,	and	catalyCEST	MRI	studies	were	performed	3	h	later	using	the	same	CEST-
FISP	MRI	protocol.	An	additional	3	mice	were	scanned	with	catalyCEST	MRI	and	were	then	
euthanized	 without	 treatment,	 to	 provide	 pre-treatment	 samples	 for	 ex	 vivo	 studies.	







Winooski,	 VA)	was	 used	 to	monitor	 absorbance	 at	 405	 nm.	 The	 amount	 of	 uPA	 activity	
varied	between	0.37	and	1.20	Units	for	the	standard	curve.	
Reaction Coordinate =1- ?@AB	CDEFGH	GIJHDKLMN	GK	5.2	JJI	
?@AB	CDEFGH	GIJHDKLMN	GK	P.5	JJI			
                 Eq. [1] 
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was	 placed	 in	 500	 µL	 of	 1×	 assay	 buffer	 from	 the	 uPA	Activity	 Assay	 Kit.	 Samples	were	




after	 1.5	 h	 of	 incubation	 with	 the	 substrate.	 The	 amount	 of	 uPA	 activity	 in	 each	





The	 contrast	 agent,	 compound	5,	was	 synthesized	with	 an	overall	 yield	of	6%,	which	
followed	 a	 5-step	 synthesis	 strategy	 (Scheme	2.1).	 First,	 the	 acid	 functional	 group	 of	 4-
amino	salicylic	acid	was	protected	as	a	benzyl	ester	followed	by	protection	of	the	hydroxyl	
functional	 group	 as	 a	 benzyl	 alcohol.	 Then,	 the	 arginine	 amino	 acid	 was	 coupled	 to	 the	
amino	group	by	standard	peptide	coupling	procedures.	After	deprotection	of	the	Boc	group	
on	 the	 arginine,	 the	 glycine	 amino	 acid	 was	 coupled	 by	 standard	 peptide	 coupling	
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Figure	 2.3.	 In	 vivo	 catalyCEST	 MR	 images	 of	
baseline	mice.	 (a)	Anatomical	 images	of	 the	 three	
mice	 that	 were	 sacrificed	 after	 the	 baseline	 scan.	
(b)	Parametric	maps	of	%	CEST	signal	amplitudes	
of	 CEST	 at	 9.5	 and	 5.0	 ppm	 observe	 presence	 of	
contrast	agent	 in	the	areas	around	the	tumors.	 (c)	






	 From	 the	 activity	maps,	 the	mean	 reaction	 coordinate	 for	 each	 of	 the	 images	was	
obtained,	and	the	average	of	each	group	was	taken	(Figure	2.5).	The	average	of	the	mean	
Figure	 2.5.	 Chart	 of	 mean	
reaction	 coordinates	 for	
baseline,	saline,	and	BTZ	groups.	
The	 bar	 graph	 on	 the	 left	
indicates	 the	 average	 value	 of	
the	 mean	 reaction	 coordinate	
for	 the	 baseline	 scans	 of	 the	 10	
mice.	 The	 bar	 in	 the	 middle	
indicates	 the	 average	 value	 of	
the	 mean	 reaction	 coordinate	
for	the	3	scans	acquired	3	h	post	
saline	 injection.	 The	 bar	 on	 the	
right	 indicates	 the	 average	
value	 of	 the	 mean	 reaction	






















Figure	 2.4.	 In	 vivo	catalyCEST	MR	 images	of	mice	before	and	after	treatment	with	BTZ	or	saline.	Each	mouse	
was	 imaged	 at	 baseline	 and	 then	 at	 3	 h	 post-injection.	 (a,	 d)	 Anatomical	 images	 of	 the	 four	 mice	 that	 were	
injected	with	BTZ	(a)	and	with	saline	(d).	(b,	e)	Parametric	maps	of	%	CEST	signal	amplitudes	of	CEST	at	9.5	and	
5.0	ppm	observe	presence	of	contrast	agent	 in	the	areas	around	 the	tumors	 for	mice	 injected	with	BTZ	(b)	and	

















































Figure	 2.6.	 Chart	 of	 reaction	
coordinate	 vs.	 the	 tumor	volume.	




Additionally,	 the	 average	 of	 the	 mean	 reaction	 coordinates	 before	 and	 after	






average	 baseline	 activity	was	 0.86	±	0.10	 relative	 units.	 The	 average	 activity	 after	 saline	
Figure	 2.8.	 Ex	 vivo	 uPA	 enzyme	
activity.	 The	 average	 uPA	 activity	
for	the	baseline	(3	samples),	saline-












































coordinates	 for	 before	 and	 after	
treatment	groups	of	saline	and	BTZ.	
The	 two	 bars	 on	 the	 right	 indicate	
the	 average	 value	 of	 the	 mean	




the	 4	 mice	 in	 the	 BTZ	 group.	 The	
standard	 deviation	 is	 shown	 for	
each	bar.	
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Figure	 2.10.	 Chart	 of	 uPA	 activity	



























Figure	 2.9.	 Chart	 of	 uPA	
activity	of	 the	 frozen	tumors	vs.	










for	 the	 deprotection	 of	 Boc	 with	 minor	 deprotection	 of	 other	 groups.	 Also,	 HPLC	
purification	 was	 required	 for	 this	 step	 due	 to	 the	 polarity	 of	 the	 ammonium	 salt.	 The	
synthesis	 of	 compound	 4	 originally	 used	 benzotriazol-1-yloxy	
tris(dimethylamino)phosphonium	 hexafluorophosphate	 (BOP)	 and	 hydroxybenzotriazole	
(HOBt)	as	the	coupling	reagents.24	However,	in	order	to	increase	yield,	BOP	and	HOBt	were	









	 Previous	 preliminary	 work	 indicated	 that	 a	 decrease	 in	 uPA	 activity	 could	 be	




where	 the	 contrast	 agent	 was	 injected	 subcutaneously.	 Tumor	 uptake	 could	 have	 been	
influenced	 by	 the	 formulation	 of	 the	 contrast	 agent.	 Additionally,	 injecting	 the	 agent	
subcutaneously	may	have	led	to	poor	uptake	due	to	the	biology	of	the	tumor.	In	the	future,	
injecting	 the	 contrast	 agent	 IV	 should	be	 considered	 to	 improve	 the	uptake	 in	 the	 tumor	
and	 move	 to	 a	 more	 clinically	 applicable	 approach.	 The	 averages	 of	 the	 mean	 reaction	
coordinates	for	extracellular	uPA	activity	for	the	baseline,	saline,	and	BTZ	groups	(Figure	
2.5)	were	statistically	the	same	(baseline	vs.	BTZ,	p	>	0.05;	saline	vs.	BTZ,	p	>	0.05;	baseline	
vs.	 saline,	 p	 >	 0.05).	 Additionally,	 there	 was	 no	 statistical	 difference	 before	 and	 after	
treatment	 of	 BTZ	 (p	 >0.05)	 (Figure	 2.7).	 No	 correlation	 was	 found	 between	 the	 mean	
reaction	coordinates	and	the	tumor	volumes	(Figure	2.6)	with	an	R2	value	of	0.034.	Based	






of	 the	 baseline,	 saline,	 and	 BTZ	 groups	 (Figure	 2.8)	 were	 also	 statistically	 the	 same	
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(baseline	vs.	BTZ,	p	>	0.05;	saline	vs.	BTZ,	p	>	0.05;	baseline	vs.	saline,	p	>	0.05).	There	was	
no	 correlation	 found	between	uPA	activity	 and	 tumor	 volume	 (R2	=	0.004)	 (Figure	2.9).	
Lastly,	 no	 correlation	 was	 found	 between	 mean	 reaction	 coordinate	 and	 uPA	 activity	
(Figure	2.10)	with	an	R2	value	of	0.068.	The	in	vivo	and	the	ex	vivo	results	may	be	difficult	
to	 correlate	 because	 extracellular	 uPA	 activity	 in	vivo	 is	 being	 compared	 to	 intracellular	
activity	 ex	vivo.	 The	 results	 for	 the	 ex	vivo	 data	 may	 have	 been	 inconclusive	 due	 to	 the	
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In	 this	 project,	 we	 attempted	 to	 detect	 therapeutic	 response	 by	 monitoring	 uPA	





alternative	 way	 to	 approach	 the	 synthesis	 is	 to	 use	 solid	 phase	 peptide	 synthesis.	 This	
technique	is	fast	and	robust,	because	the	solid	support	allows	for	easier	purification.	Once	
the	peptide	is	cleaved	from	the	resin,	the	peptide	can	be	coupled	to	compound	1,	and	the	
resulting	molecule	 can	 be	 deprotected	 to	 yield	 the	 contrast	 agent.	 Wang	 resin	 and	 2-
chlorotrityl	chloride	resin	can	be	used	to	produce	a	carboxylic	acid	after	cleavage	from	the	
solid	support,	which	is	needed	to	couple	the	peptide	to	the	amino	group	of	compound	1.		
		 The	specificity	of	 the	peptide	chain	should	also	be	considered.	 In	vivo,	uPA	cleaves	
the	Arg-Val	bond	in	the	sequence	CPGR-VVGG of	plasminogen	to	activate	plasmin,	so	many	












Table	 3.1.	 Table	 of	 proposed	 uPA-




	 One	 way	 to	 minimize	 the	 biological	 variation	 is	 to	 perform	 more	 precise	 cell	
injections	 into	 the	 flank	 of	 the	mice.	 The	 tumors	 that	 grew	 in	 the	mice	 presented	 in	 the	
previous	 chapter	 were	 not	 uniform.	 Some	 tumors	 grew	 very	 fast	 and	 became	 necrotic,	
which	 can	 be	 attributed	 to	 a	 highly	 varied	 distribution	 of	 cells	 between	 the	 injections.	
Additionally,	 some	 of	 the	 tumors	 grew	 within	 the	 muscle	 tissue	 and	 were	 not	 truly	
subcutaneous,	which	can	result	in	varying	biology	between	tumors.	On	the	other	hand,	to	
be	more	clinically	relevant,	orthotropic	xerographs	may	be	a	better	approach.	These	types	
of	 tumors	 can	more	closely	mimic	 the	vasculature	and	drug	accessibility.	Other	 cell	 lines	
(e.g.,	breast,	bladder,	stomach,	etc.)	could	also	be	used	to	see	if	the	change	in	uPA	is	more	
significant	in	those	cell	lines.	
	 In	 this	 project,	 only	 10	 mice	 were	 imaged	 due	 to	 the	 limited	 material	 that	 was	
synthesized.	However,	a	larger	group	of	mice	should	be	used	for	better	statistical	analysis.	
About	10-12	mice	per	group	 (baseline,	BTZ-treated,	 and	saline-treated)	would	be	a	good	
starting	point.	 In	 addition	 to	 a	 larger	 sample	 size,	more	 time	points	 can	be	 explored,	 for	
instance,	 48	 h	 or	 greater	 after	 initiating	 treatment.	 Because	 there	 was	 no	 statistically	
significant	difference	between	before	and	after	treatment	with	BTZ	scans,	the	therapy	may	
need	 more	 time	 to	 decrease	 the	 uPA	 activity.	 Some	 other	 time	 points	 that	 could	 be	
investigated	are	12	h,	48	h,	and/or	72	h	post	 injection.	Along	 the	same	 lines,	 the	dose	of	
BTZ	administered	could	be	increased	to	generate	a	faster	or	greater	change	in	uPA	activity.	
However,	a	standard	high	dose	for	mice	ranges	from	0.5	–	1.0	mg/kg,5	while	in	our	study,	
we	 used	 2.0	 mg/kg.	 Alternatively,	 a	 different	 proteasome	 inhibitor	 could	 be	 injected.	
Carfilzomib,	 a	 more	 recently	 FDA	 approved	 drug,	 has	 been	 shown	 to	 be	 a	 successful	
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substitute	for	BTZ.6	Additionally,	a	longer	longitudinal	study	could	be	done,	where	the	mice	
receive	 a	 regimen	of	 proteasome	 inhibitor	 rather	 than	 one	 injection.	 Ideally,	 the	 gradual	
decrease	of	uPA	could	be	monitored	though	CEST	MRI.	However,	such	a	study	would	not	
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